327 related articles for article (PubMed ID: 23211222)
1. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Cubillo A; Rodriguez-Pascual J; López-Ríos F; Plaza C; García E; Álvarez R; de Vicente E; Quijano Y; Hernando O; Rubio C; Perea S; Sanchez G; Hidalgo M
Am J Clin Oncol; 2016 Jun; 39(3):236-42. PubMed ID: 24517959
[TBL] [Abstract][Full Text] [Related]
3. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
5. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Fokas E; Conradi L; Weiss C; Sprenger T; Middel P; Rau T; Dellas K; Kitz J; Rödel F; Sauer R; Rüschoff J; Beissbarth T; Arnold D; Ghadimi BM; Rödel C; Liersch T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):992-9. PubMed ID: 24210078
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Glynne-Jones R; Mawdsley S; Harrison M
Acta Oncol; 2010 Apr; 49(3):278-86. PubMed ID: 20180626
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Wong NS; Fernando NH; Nixon AB; Cushman S; Aklilu M; Bendell JC; Morse MA; Blobe GC; Ashton J; Pang H; Hurwitz HI
Anticancer Res; 2011 Jan; 31(1):255-61. PubMed ID: 21273607
[TBL] [Abstract][Full Text] [Related]
10. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Sun PL; Li B; Ye QF
Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Brunner S; von Moos R; Mey U; Camenisch Gross U; Freyholdt T; Cathomas R
Oncol Res Treat; 2014; 37(11):646-52. PubMed ID: 25427581
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F; Gonzalez D; Cunningham D; Hulkki Wilson S; Peckitt C; Giralt J; Glimelius B; Roselló Keränen S; Wotherspoon A; Brown G; Tait D; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1430-6. PubMed ID: 24582914
[TBL] [Abstract][Full Text] [Related]
17. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K; Treschl A; Mai S; Barreto-Miranda M; Kienle P; Ströbel P; Erben P; Woernle C; Dinter D; Kähler G; Hochhaus A; Post S; Willeke F; Wenz F; Hofheinz RD;
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1487-93. PubMed ID: 19131187
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
